Age 0 3 0 3 B-age
≥ 4 5 4 5 O
70 6 8 6 8 B-upper_bound
years 9 14 9 14 I-lower_bound
OR 15 17 15 17 O
KPS 18 21 18 21 B-clinical_variable
≤ 22 23 22 23 O
70 24 26 24 26 O

Any 0 3 27 30 O
nodal 4 9 31 36 B-clinical_variable
or 10 12 37 39 I-clinical_variable
extranodal 13 23 40 50 I-clinical_variable
tumor 24 29 51 56 I-clinical_variable
mass 30 34 57 61 I-clinical_variable
≥7 35 37 62 64 O
cm 37 39 64 66 I-lower_bound
in 40 42 67 69 O
greatest 43 51 70 78 O
dimension 52 61 79 88 O

Contraindication 0 16 89 105 O
to 17 19 106 108 O
use 20 23 109 112 O
of 24 26 113 115 O
rituximab 27 36 116 125 B-treatment
or 37 39 126 128 O
prednisone 40 50 129 139 B-treatment

Cytopenias 0 10 140 150 B-chronic_disease
( 11 12 151 152 O
leukocytes 12 22 152 162 B-clinical_variable
< 23 24 163 164 O
1 24 25 164 165 B-upper_bound
× 26 27 166 167 I-upper_bound
109 28 31 168 171 I-upper_bound
/ 31 32 171 172 I-upper_bound
L 32 33 172 173 I-upper_bound
and/or 34 40 174 180 O
platelets 41 50 181 190 B-clinical_variable
, 51 52 191 192 O
100 52 55 192 195 B-upper_bound
× 56 57 196 197 I-upper_bound
109 58 61 198 201 I-upper_bound
/ 61 62 201 202 I-upper_bound
L 62 63 202 203 I-upper_bound
) 63 64 203 204 O

Enrollment 0 10 205 215 O
in 11 13 216 218 O
a 14 15 219 220 O
Phase 16 21 221 226 B-treatment
I 22 23 227 228 I-treatment
trial 24 29 229 234 I-treatment

Evidence 0 8 235 243 O
of 9 11 244 246 O
active 12 18 247 253 O
hepatitis 19 28 254 263 B-chronic_disease
B 29 30 264 265 I-chronic_disease
infection 31 40 266 275 I-chronic_disease
( 41 42 276 277 O
i.e. 42 46 277 281 O
patients 47 55 282 290 O
testing 56 63 291 298 O
positive 64 72 299 307 O
hepatitis 73 82 308 317 O
B 83 84 318 319 O
surface 85 92 320 327 O
antigen 93 100 328 335 O
or 101 103 336 338 O
viral 104 109 339 344 O
DNA 110 113 345 348 O
by 114 116 349 351 O
PCR 117 120 352 355 B-treatment
analysis 121 129 356 364 I-treatment
) 129 130 364 365 O

Fluent 0 6 366 372 B-language_fluency
in 7 9 373 375 I-language_fluency
English 10 17 376 383 I-language_fluency
( 18 19 384 385 O
because 19 26 385 392 O
not 27 30 393 396 O
all 31 34 397 400 O
components 35 45 401 411 O
of 46 48 412 414 O
the 49 52 415 418 O
GA 53 55 419 421 O
have 56 60 422 426 O
been 61 65 427 431 O
validated 66 75 432 441 O
in 76 78 442 444 O
other 79 84 445 450 O
languages 85 94 451 460 O
) 94 95 460 461 O

History 0 7 462 469 O
of 8 10 470 472 O
any 11 14 473 476 O
serious 15 22 477 484 O
adverse 23 30 485 492 O
reaction 31 39 493 501 O
to 40 42 502 504 O
either 43 49 505 511 O
a 50 51 512 513 O
corticosteroid 52 66 514 528 B-treatment
or 67 69 529 531 O
rituximab 70 79 532 541 B-treatment
not 80 83 542 545 O
including 84 93 546 555 O
rituximab 94 103 556 565 B-clinical_variable
infusion 104 112 566 574 I-clinical_variable
reactions 113 122 575 584 I-clinical_variable
≤ 123 124 585 586 O
Grade 125 130 587 592 B-upper_bound
3 131 132 593 594 I-upper_bound

Indolent 0 8 595 603 O
histology 9 18 604 613 O
with 19 23 614 618 O
one 24 27 619 622 O
of 28 30 623 625 O
the 31 34 626 629 O
following 35 44 630 639 O
markers 45 52 640 647 O
of 53 55 648 650 O
large 56 61 651 656 O
tumor 62 67 657 662 B-cancer
burden 68 74 663 669 O
( 75 76 670 671 O
67 76 78 671 673 O
) 78 79 673 674 O

Intended 0 8 675 683 O
initial 9 16 684 691 O
treatment 17 26 692 701 B-treatment
to 27 29 702 704 O
include 30 37 705 712 O
≥2 38 40 713 715 O
cycles 41 47 716 722 O
of 48 50 723 725 O
R 51 52 726 727 B-treatment
- 52 53 727 728 I-treatment
CHOP 53 57 728 732 I-treatment
, 57 58 732 733 O
R 59 60 734 735 B-treatment
- 60 61 735 736 I-treatment
EPOCH 61 66 736 741 I-treatment
or 67 69 742 744 O
R 70 71 745 746 B-treatment
- 71 72 746 747 I-treatment
CEPP 72 76 747 751 I-treatment
using 77 82 752 757 O
standard 83 91 758 766 O
doses 92 97 767 772 O
and 98 101 773 776 O
schedule.(68 102 114 777 789 O
, 114 115 789 790 O
69 116 118 791 793 O
) 118 119 793 794 O
R 120 121 795 796 O
- 121 122 796 797 O
CHOP 122 126 797 801 O
chemoimmunotherapy 127 145 802 820 B-treatment
may 146 149 821 824 O
be 150 152 825 827 O
given 153 158 828 833 O
every 159 164 834 839 O
14 165 167 840 842 O
days 168 172 843 847 O
or 173 175 848 850 O
every 176 181 851 856 O
21 182 184 857 859 O
days 185 189 860 864 O

Leukemic 0 8 865 873 B-cancer
phase 9 14 874 879 I-cancer
( 15 16 880 881 O
malignant 16 25 881 890 B-clinical_variable
cells 26 31 891 896 I-clinical_variable
≥5 32 34 897 899 O
x 35 36 900 901 I-lower_bound
109 37 40 902 905 I-lower_bound
/ 40 41 905 906 I-lower_bound
L 41 42 906 907 I-lower_bound
) 42 43 907 908 O

Must 0 4 909 913 O
be 5 7 914 916 O
starting 8 16 917 925 O
a 17 18 926 927 O
new 19 22 928 931 O
chemotherapy 23 35 932 944 B-treatment
regimen 36 43 945 952 I-treatment
( 44 45 953 954 O
patients 45 53 954 962 O
whose 54 59 963 968 O
treatment 60 69 969 978 B-treatment
regimen 70 77 979 986 I-treatment
includes 78 86 987 995 O
an 87 89 996 998 O
immunomodulatory 90 106 999 1015 B-treatment
agent 107 112 1016 1021 I-treatment
such 113 117 1022 1026 O
as 118 120 1027 1029 O
lenalidomide 121 133 1030 1042 B-treatment
or 134 136 1043 1045 O
small 137 142 1046 1051 B-treatment
molecule 143 151 1052 1060 I-treatment
targeted 152 160 1061 1069 I-treatment
agents 161 167 1070 1076 I-treatment
such 168 172 1077 1081 O
as 173 175 1082 1084 O
Ibrutinib 176 185 1085 1094 B-treatment
or 186 188 1095 1097 O
Idelelasib 189 199 1098 1108 B-treatment

Must 0 4 1109 1113 O
meet 5 9 1114 1118 O
criteria 10 18 1119 1127 O
for 19 22 1128 1131 O
initiation 23 33 1132 1142 O
of 34 36 1143 1145 O
treatment 37 46 1146 1155 B-treatment

Pathologically 0 14 1156 1170 O
confirmed 15 24 1171 1180 O
NHL 25 28 1181 1184 B-clinical_variable

Pathologically 0 14 1185 1199 O
confirmed 15 24 1200 1209 O
diagnosis 25 34 1210 1219 O
of 35 37 1220 1222 O
DLBCL 38 43 1223 1228 B-cancer
, 43 44 1228 1229 O
with 45 49 1230 1234 O
or 50 52 1235 1237 O
without 53 60 1238 1245 O
simultaneous 61 73 1246 1258 O
or 74 76 1259 1261 O
antecedent 77 87 1262 1272 O
indolent 88 96 1273 1281 O
lymphoma 97 105 1282 1290 B-cancer

Patients 0 8 1291 1299 O
enrolled 9 17 1300 1308 O
on 18 20 1309 1311 O
another 21 28 1312 1319 O
clinical 29 37 1320 1328 O
trial 38 43 1329 1334 O
which 44 49 1335 1340 O
prohibits 50 59 1341 1350 O
the 60 63 1351 1354 O
use 64 67 1355 1358 O
of 68 70 1359 1361 O
pre 71 74 1362 1365 O
- 74 75 1365 1366 O
phase 75 80 1366 1371 O
therapy 81 88 1372 1379 B-treatment
or 89 91 1380 1382 O
any 92 95 1383 1386 O
of 96 98 1387 1389 O
its 99 102 1390 1393 O
components 103 113 1394 1404 O

Patients 0 8 1405 1413 B-clinical_variable
scoring 9 16 1414 1421 I-clinical_variable
≥ 17 18 1422 1423 O
11 19 21 1424 1426 B-lower_bound
on 22 24 1427 1429 O
the 25 28 1430 1433 O
BOMC 29 33 1434 1438 O
( 34 35 1439 1440 O
implying 35 43 1440 1448 O
cognitive 44 53 1449 1458 B-chronic_disease
impairment 54 64 1459 1469 I-chronic_disease
) 64 65 1469 1470 O
will 66 70 1471 1475 O
be 71 73 1476 1478 O
excluded 74 82 1479 1487 O
since 83 88 1488 1493 O
their 89 94 1494 1499 O
ability 95 102 1500 1507 O
to 103 105 1508 1510 O
reliably 106 114 1511 1519 O
complete 115 123 1520 1528 O
the 124 127 1529 1532 O
questionnaire 128 141 1533 1546 O
will 142 146 1547 1551 O
be 147 149 1552 1554 O
in 150 152 1555 1557 O
doubt 153 158 1558 1563 O
Subjects 159 167 1564 1572 O
meeting 168 175 1573 1580 O
the 176 179 1581 1584 O
following 180 189 1585 1594 O
criteria 190 198 1595 1603 O
will 199 203 1604 1608 O
be 204 206 1609 1611 O
excluded 207 215 1612 1620 O
from 216 220 1621 1625 O
enrollment 221 231 1626 1636 O
in 232 234 1637 1639 O
the 235 238 1640 1643 O
pre 239 242 1644 1647 O
- 242 243 1647 1648 O
phase 243 248 1648 1653 O
arm 249 252 1654 1657 O
of 253 255 1658 1660 O
the 256 259 1661 1664 O
study 260 265 1665 1670 O
, 265 266 1670 1671 O
but 267 270 1672 1675 O
may 271 274 1676 1679 O
be 275 277 1680 1682 O
included 278 286 1683 1691 O
in 287 289 1692 1694 O
the 290 293 1695 1698 O
GA 294 296 1699 1701 O
only 297 301 1702 1706 O
arm 302 305 1707 1710 O

Patients 0 8 1711 1719 O
with 9 13 1720 1724 O
evidence 14 22 1725 1733 O
of 23 25 1734 1736 O
past 26 30 1737 1741 O
infection 31 40 1742 1751 B-chronic_disease
without 41 48 1752 1759 O
active 49 55 1760 1766 O
viremia 56 63 1767 1774 B-chronic_disease
( 64 65 1775 1776 O
i.e. 65 69 1776 1780 O
positive 70 78 1781 1789 O
hepatitis 79 88 1790 1799 B-chronic_disease
B 89 90 1800 1801 I-chronic_disease
core 91 95 1802 1806 O
antibody 96 104 1807 1815 O
, 104 105 1815 1816 O
negative 106 114 1817 1825 O
hepatitis 115 124 1826 1835 B-chronic_disease
B 125 126 1836 1837 I-chronic_disease
surface 127 134 1838 1845 I-chronic_disease
antigen 135 142 1846 1853 I-chronic_disease
and 143 146 1854 1857 O
negative 147 155 1858 1866 O
hepatitis 156 165 1867 1876 O
B 166 167 1877 1878 O
DNA 168 171 1879 1882 B-clinical_variable
PCR 172 175 1883 1886 I-clinical_variable
) 175 176 1886 1887 O
will 177 181 1888 1892 O
be 182 184 1893 1895 O
treated 185 192 1896 1903 O
with 193 197 1904 1908 O
entecavir 198 207 1909 1918 B-treatment
as 208 210 1919 1921 O
per 211 214 1922 1925 O
institutional 215 228 1926 1939 O
guidelines 229 239 1940 1950 O

Previously 0 10 1951 1961 O
untreated 11 20 1962 1971 O
for 21 24 1972 1975 O
DLBCL 25 30 1976 1981 B-cancer

Serous 0 6 1982 1988 B-chronic_disease
effusion 7 15 1989 1997 I-chronic_disease
( 16 17 1998 1999 O
plural 17 23 1999 2005 B-chronic_disease
effusion 24 32 2006 2014 I-chronic_disease
or 33 35 2015 2017 O
peritoneal 36 46 2018 2028 B-chronic_disease
ascites 47 54 2029 2036 I-chronic_disease
) 54 55 2036 2037 O

Substantial 0 11 2038 2049 O
splenomegaly 12 24 2050 2062 B-chronic_disease

Systemic 0 8 2063 2071 B-chronic_disease
fungal 9 15 2072 2078 I-chronic_disease
infection 16 25 2079 2088 I-chronic_disease

Uncontrolled 0 12 2089 2101 O
diabetes 13 21 2102 2110 B-chronic_disease
mellitus 22 30 2111 2119 I-chronic_disease

Ureteral 0 8 2120 2128 B-chronic_disease
compression 9 20 2129 2140 I-chronic_disease

patients 0 8 2141 2149 O
being 9 14 2150 2155 O
treated 15 22 2156 2163 O
with 23 27 2164 2168 O
a 28 29 2169 2170 O
single 30 36 2171 2177 B-treatment
agent 37 42 2178 2183 I-treatment
monoclonal 43 53 2184 2194 I-treatment
antibody 54 62 2195 2203 I-treatment

≥3 0 2 2204 2206 O
nodal 3 8 2207 2212 O
masses 9 15 2213 2219 O
that 16 20 2220 2224 O
are 21 24 2225 2228 O
each 25 29 2229 2233 O
≥3 30 32 2234 2236 O
cm 33 35 2237 2239 I-lower_bound
in 36 38 2240 2242 O
greatest 39 47 2243 2251 O
dimension 48 57 2252 2261 O

≥60 0 3 2262 2265 O
years 4 9 2266 2271 I-lower_bound
old 10 13 2272 2275 O

